Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Doses of KQ-791 in Subjects With Type 2 Diabetes
NCT02445911Phase 1Completed
- Sponsor
- Kaneq Bioscience Ltd.
- Start
- Jun 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of KQ-791 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Kaneq Bioscience Ltd. Primary endpoints: Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo at Day 29 and Number of Participants With One or More Treatment-Emergent Adverse Events at Day 29. Started Jun 2015; status: completed.
02
Drugs
KQ-791
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02445911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02445911.